DR

DarioHealth CorpNASDAQ DRIO Stock Report

Last reporting period 30 Jun, 2024

Updated 25 Nov, 2024

Last price

Market cap $B

0.029

Micro

Exchange

XNAS - Nasdaq

DRIO Stock Analysis

DR

Uncovered

DarioHealth Corp is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-14/100

Low score

Market cap $B

0.029

Dividend yield

Shares outstanding

25.872 B

DarioHealth Corp. is a digital therapeutics company, which engages in the research, development, and sale of pharmaceutical products. The company is headquartered in New York City, New York and currently employs 241 full-time employees. The company went IPO on 2013-03-08. DarioHealth operates at the intersection of life sciences, behavioral science, and software technology to deliver integrated and engaging digital therapeutics interventions. DarioHealth offers digital therapeutics solutions covering multiple chronic conditions including diabetes, hypertension, weight management, musculoskeletal and behavioral health within one integrated technology platform. Its products include Dario Blood Glucose Monitoring Starter Kit and Dario Blood Pressure Monitoring System. Its Dario Blood Glucose Monitoring Starter Kit is pocket-sized smartphone blood glucose meter that measure sugar levels. Its Dario Blood Pressure Monitoring System is a blood pressure monitoring system used to measure blood pressure, which allows to store all your readings in the Dario App. Its Dario mobile application, the Dario Blood sugar (glucose) meter enables to track and check blood sugar (glucose) in real-time.

View Section: Eyestock Rating